Latest Advances and Insights in Weight Management, Healthy Living, and Nutrition - January 2026

The past week has seen notable progress in weight management treatments, significant shifts in national nutrition policy, and emerging data on exercise and health that promise to reshape public understanding and practices around healthy living and eating.

FDA Approval of First Daily Oral GLP-1 Treatment for Weight Management

In a groundbreaking development, the US Food and Drug Administration approved Novo Nordisk's once-daily oral GLP-1 medication for weight management. Clinical trial data from the 64-week Phase 3 OASIS 4 study showed an average weight reduction of 16.6% from baseline with full adherence, compared to 2.7% in the placebo group. Notably, about 30% of participants receiving oral semaglutide achieved a weight loss of 20% or more.

Beyond weight loss, this therapy demonstrated a reduction in major cardiovascular events by approximately 20% among patients with heart disease, marking it as a significant advancement in both obesity and cardiovascular risk management.

This oral formulation offers a convenient alternative to injectable GLP-1 therapies, potentially increasing accessibility and adherence.

Roche's Dual GLP-1/GIP Receptor Agonist Shows Promise in Phase 2 Trial

Roche announced positive results for their experimental obesity drug, CT-388, a once-weekly subcutaneous injection combining GLP-1 and GIP receptor agonists. Over 48 weeks, the highest dose group (24 mg) achieved a substantial placebo-adjusted weight loss of 22.5%. More than half (54%) of participants reached a BMI under 30 kg/m² compared to 13% in the placebo group.

This dual agonist approach could introduce new effective pharmacological tools pending Phase 3 trial outcomes anticipated to start soon.

Innovative Primary Care Model PATHWEIGH Reduces Population Weight Gain

A large-scale study involving 274,182 patients across 56 Colorado primary care clinics tested the PATHWEIGH approach, which gates weight management into routine medical care with enhanced support tools. The intervention reduced average population weight gain by 0.58 kg over 18 months.

Additionally, patients were 23% more likely to receive weight-related care, and prescriptions for anti-obesity drugs doubled. This data underscores the potential for systematic integration of weight care in standard medical practices to effectively combat obesity at the population level.

Historic Reset in US Nutrition Policy Emphasizes Whole, Nutrient-Dense Foods

The newly released Dietary Guidelines for Americans 2025-2030 represent the most significant federal nutrition policy revision in decades. The guidelines place a clear emphasis on the value of real, whole foods — specifically protein, dairy, vegetables, fruits, healthy fats, and whole grains.

There is a strong push to reduce consumption of added sugars, refined carbohydrates, and highly processed foods. Notably, full-fat dairy and protein are recommended at every meal, overturning decades-old low-fat dogma with evidence supporting healthy fats' role in long-term health.

Public Awareness and Market Dynamics of GLP-1 Weight-Loss Drugs

Recent Pew Research data reveal that 53% of Americans report hearing about GLP-1 medications like Ozempic and Wegovy extremely or very often, with awareness highest in women aged 50 and older (68%).

Correspondingly, Novo Nordisk reported $31.1 billion in revenue from GLP-1 drugs in 2024, a near tripling from $11.9 billion in 2022 and representing 70% of total company revenue. This reflects a strong market uptake and the growing role of GLP-1 therapies in managing obesity at scale.

Additional Insights on Exercise and Health

Complementing advances in medication and nutrition, recent exercise studies reaffirm the health benefits of physical activity. Meeting minimum guidelines for moderate to vigorous exercise can reduce cardiovascular disease mortality by 22% to 31%. Vigorous activity was linked to a 31% lower risk of cardiovascular death, with further risk reductions for those who exceed recommended activity levels.

Moreover, brief exercise sessions, about 15-20 minutes of vigorous activity, have been shown to build emotional resilience, supporting mental health and potentially enhancing adherence to healthy behaviors.

Emerging Challenges: Prediabetes in Youth and Expanding Definitions of Obesity

New data highlight concerning trends in youth health, with nearly 1 in 3 adolescents (ages 12-17) classified as prediabetic, signaling elevated future risks for type 2 diabetes. This trend is linked closely with rising obesity rates, which may be underestimated under traditional BMI-only criteria.

Recent studies suggest up to 75% of U.S. adults may meet expanded criteria for obesity when incorporating comprehensive body measurements, compared to earlier estimates around 40% based on BMI alone, pointing to a growing public health challenge.

Summary

The latest week’s findings collectively emphasize the multifaceted approach required to tackle obesity and promote health. The approval and commercial availability of new oral and injectable GLP-1 therapies mark a transformative step forward, alongside evolving primary care models and historic nutrition policy reforms that encourage whole food consumption over processed alternatives.

These advances, combined with evidence underpinning exercise’s powerful benefits, provide a robust framework for reducing obesity-related risks and improving population health outcomes.

Sources

• https://www.prnewswire.com/apac/news-releases/us-fda-approves-first-daily-oral-glp1-treatment-for-weight-management-showing-comparable-results-to-injectable-therapy-302671957.html
• https://www.roche.com/media/releases/med-cor-2026-01-27
• https://www.sciencedaily.com/releases/2026/01/260116035317.htm
• https://www.usda.gov/about-usda/news/press-releases/2026/01/07/kennedy-rollins-unveil-historic-reset-us-nutrition-policy-put-real-food-back-center-health
• https://www.pewresearch.org/short-reads/2026/01/23/6-facts-about-obesity-and-weight-loss-drugs-in-the-u-s/